Deferred Tax Assets, Valuation Allowance of Summit Therapeutics Inc. from 31 Jan 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Summit Therapeutics Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Jan 2018 to 31 Dec 2025.
  • Summit Therapeutics Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $133,161,000, a 39% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Summit Therapeutics Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $133,161,000 +$37,573,000 +39% 31 Dec 2025 10-K 23 Feb 2026 2025 FY
Q4 2024 $95,588,000 +$10,837,000 +13% 31 Dec 2024 10-K 23 Feb 2026 2025 FY
Q4 2023 $84,751,000 +$20,735,000 +32% 31 Dec 2023 10-K 23 Feb 2026 2025 FY
Q4 2022 $64,016,000 +$12,270,000 +24% 31 Dec 2022 10-K 23 Feb 2026 2025 FY
Q4 2021 $51,746,000 +$22,517,000 +77% 31 Dec 2021 10-K 24 Feb 2025 2024 FY
Q4 2020 $29,229,000 +$10,838,000 +59% 31 Dec 2020 10-K/A 21 Dec 2022 2021 FY
Q4 2019 $18,391,000 +$1,795,000 +11% 31 Dec 2019 10-K 31 Mar 2021 2020 FY
Q4 2018 $16,596,000 -$1,687,000 -9.2% 31 Jan 2019 8-K 29 Sep 2020 2020 Q2
Q4 2017 $18,283,000 31 Jan 2018 8-K 29 Sep 2020 2020 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.